Streetbeat News

Regulatory

KO

Coca-Cola's CFO expressed uncertainty regarding the duration of the impact from the Middle East conflict on the company's operations during a conference call.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:57 pm

AKLI

Akili announced its intention to continue seeking FDA marketing authorization for its EndeavorOTC product, a move that underscores the company's commitment to bringing its digital therapeutic solutions to market.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:54 pm

CYCC

GMM

MMM

3M shares surged 8.3% after a Q1 earnings beat. Cyclacel Pharmaceuticals soared 103% following the withdrawal of its Form S-1 registration and announcing an $8 million private placement. Global Mofy Metaverse (GMM) jumped 62% as it collaborates with Heartdub to use NVIDIA Omniverse for developing the GAUSSPEED Generative Video AI Platform.

Portfolio Pulse from ryanfaloona@benzinga.com

April 30, 2024 | 12:45 pm

BYDDF

BYDDY

BYD Co Ltd is recalling 16,666 Seagull EVs due to faulty reversing cameras caused by software issues in vehicles produced between April 7, 2023, and May 31, 2023. The company plans to address the problem with an over-the-air software upgrade, and for vehicles that cannot be fixed remotely, BYD will contact customers for a direct software upgrade. This recall comes as BYD maintains its position as the top EV maker in China, with a 13.44% increase in sales of new energy vehicles in the first quarter of 2024.

Portfolio Pulse from Anan Ashraf

April 30, 2024 | 12:42 pm

WVE

Wave Life Sciences Ltd. (NASDAQ:WVE) announced the approval of its first clinical trial application for the RestorAATion-2 trial of WVE-006, aimed at treating alpha-1 antitrypsin deficiency (AATD). WVE-006, a first-in-class RNA editing oligonucleotide, does not use a lipid nanoparticle delivery system and is subcutaneously administered. The trial will evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in individuals with AATD. GSK holds the exclusive global license for WVE-006, with development and commercialization responsibilities transferring to GSK after the completion of the RestorAATion-2 study. Wave Life Sciences is also advancing its RNA editing pipeline across various targets.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:40 pm

BTCUSD

ETHUSD

Hong Kong's debut of Bitcoin and Ethereum spot ETFs saw a modest first-day trading volume of $12 million, significantly lower than the U.S.'s first Bitcoin ETF launch volume of $4.6 billion. The difference highlights varying investor appetites and regulatory landscapes, with Hong Kong adopting a more lenient approach towards Ethereum compared to the U.S., where regulatory uncertainties persist. The event underscores the global financial community's interest in the future of cryptocurrency ETFs and regulatory frameworks.

Portfolio Pulse from Murtuza Merchant

April 30, 2024 | 12:33 pm

AGRI

AgriFORCE has been granted an Australian patent, number 2018215090, for a new type of flour that is high in fiber and protein but low in carbohydrates. This innovation also extends to sweetened liquids, sweeteners, and cereals, including methods for their production.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:31 pm

NKLA

Nikola Corporation (NASDAQ:NKLA) is proposing a reverse stock split to regain Nasdaq compliance and enhance financial stability. Chairman Steven Shindler addressed stockholder questions in a video, emphasizing the split's role in raising capital efficiently and attracting a broader investor base. The proposal is part of five to be voted on at the June 5, 2024, Annual Stockholder Meeting. NKLA encourages stockholder votes in favor, highlighting the move's potential to prevent delisting and reset financial foundations.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:29 pm

NRBO

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced its cardiometabolic assets, DA-1241 and DA-1726, will be presented at the EASL Congress 2024 and the ADA 84th Scientific Sessions in June. DA-1241 has completed enrollment for Part 1 of its Phase 2a clinical trial for MASH treatment, and DA-1726 has begun its Phase 1 trial for obesity treatment. Top-line data for DA-1726 is expected in Q3 2024 and Q1 2025. The presentations highlight the pre-clinical data's recognition and the progress of both programs.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 12:28 pm

TSLA

Elon Musk criticized the SEC on Lex Fridman's podcast, highlighting its failure to protect retail investors from hedge funds' market manipulation and short selling. Musk's comments followed the U.S. Supreme Court's rejection of his appeal against a securities fraud settlement with the SEC, related to his 2018 tweet about privatizing Tesla. This criticism comes amid Tesla's stock fluctuations and a recent rally over 15% after a deal with the Chinese government for full self-driving technology.

Portfolio Pulse from Benzinga Neuro

April 30, 2024 | 12:19 pm